- Home
- »
- Medical Devices
- »
-
Heart Pump Devices Market Size & Share Report, 2026-2033GVR Report cover
![Heart Pump Device Market (2026 - 2033)Report]()
Heart Pump Device Market (2026 - 2033)
Size, Share & Trends Analysis Report By Type, By Product (Ventricular Assist Devices, Intra-Aortic Balloon Pumps, Extracorporeal Membrane Oxygenation), By End-use, By Region, And Segment Forecasts
Market Size, 2025
$4.7BMarket Estimate, 2026
$5.3BMarket Forecast, 2033
$11.0BCAGR, 2026–2033
11.1%Heart Pump Device Market Summary
The global heart pump devices market size was valued at USD 4.7 billion in 2025 and is projected to grow from USD 5.3 billion in 2026 to USD 11.0 billion by 2033, at a CAGR of 11.1% from 2026 to 2033. North America dominated the heart pump devices market with the largest revenue share of 54.6% in 2025. The increasing prevalence of heart diseases, such as coronary heart disease and cardiovascular disease, the growing demand for technologically advanced products, and growing approval from regulatory bodies are propelling the industry's growth.
Key Market Trends & Insights
- By product: Ventricular assist devices (VADs) segment held the largest market share of 69.1% in 2025.
- By type: Implanted heart pump devices segment held the largest market share of 68.3% in 2025.
- By end use: Hospitals segment held the largest market share of 81.5% in 2025.
Regional Highlights
- Largest regional market: North America (54.6% revenue share, 2025)
- By country: The U.S held the largest market share in 2025
Market Size & Forecast
- Market size in 2025: USD 4.7 Billion
- Estimated market size in 2026: USD 5.3 Billion
- Projected market size by 2033: USD 11.0 Billion
- CAGR (2026-2033): 11.1%
According to the CDC, approximately 12.1 million Americans will be suffering from atrial fibrillation by 2030.In 2022, there were 315 million cases of coronary artery disease worldwide. The increase in heart disease cases can be attributed to lifestyle changes and an aging population.
The increasing regulatory approval of heart pump devices is expected to boost market growth. In December 2024, J & J MedTech announced that the USFDA expanded the indications of the Impella 5.5 SmartAssist and Impella CP SmartAssist heat pumps for use in pediatric patients having symptomatic acute decompensated heart failure and cardiogenic shock, and additionally, they received premarket approval for the same.
Collaborative efforts allow the merging of knowledge and technical know-how from various participants in the industry. By combining insights from different organizations, researchers gain a more comprehensive understanding of the complex challenges associated with heart pump devices. This shared knowledge leads to more effective solutions, improved device designs, and enhanced patient outcomes.
For instance, in January 2024, Ultromics, a health technology enterprise centered on patient outcomes and propelled by AI, originating from the University of Oxford, UK, forged a collaborative agreement with Pfizer. The objective was to bolster the validation process and secure FDA clearance for Ultromics' AI-driven technology to detect cardiac amyloidosis. Within this alliance, Ultromics will undertake research to achieve FDA clearance for its EchoGo Amyloidosis algorithm, a medical device with Breakthrough Device Designation specifically designed to identify cardiac amyloidosis. The algorithm uses deep learning techniques to analyze routine echocardiograms, revealing cardiac amyloidosis cases that often evade detection during standard assessments.
Market Dynamics
The increasing prevalence of heart diseases, such as coronary heart disease and cardiovascular disease, the growing demand for technologically advanced products, and growing approval from regulatory bodies are propelling the industry's growth.
Regulatory approval acts as a stamp of credibility, assuring healthcare providers and patients that the heart pump devices meet stringent safety and performance standards. Approval from regulatory authorities such as the U.S. Food and Drug Administration (FDA), European regulatory bodies, and other national agencies enhances confidence among healthcare providers, patients, and payers, facilitating broader clinical adoption. Companies receiving regulatory clearance also strengthen their competitive position by differentiating their products from unapproved alternatives and expanding commercial opportunities. For instance, in December 2024, the FDA approved Johnson & Johnson MedTech’s Impella 5.5 with SmartAssist and Impella CP with SmartAssist for pediatric patients with symptomatic acute decompensated heart failure and cardiogenic shock. The approval expands access to minimally invasive left-sided heart pumps previously cleared for adults, supported by real-world data.
Regulatory clearances across multiple geographic markets further enable manufacturers to expand their global commercial footprint by improving access to diverse healthcare systems and patient populations. Compliance with evolving regulatory standards encourages companies to invest in research and development to enhance algorithm performance, clinical validation, and product reliability. In addition, regulatory approval serves as an important indicator of product quality and clinical value, strengthening investor confidence and supporting funding for technology development and market expansion. As regulatory agencies continue to establish structured pathways for AI-enabled medical devices, increasing approvals are expected to accelerate innovation, improve market accessibility, and support the long-term growth of the AI-based cardiac diagnostics market.
Extensive research and development have led to significant progress in heart pump devices. Innovations in design, materials, and operations have produced devices that are more efficient, durable, and supportive for patients with cardiac conditions. Ongoing efforts focus on reducing device size, increasing portability, and minimizing invasiveness. This trend toward miniaturization simplifies implantation and may improve patient comfort. Importantly, these improvements maintain or exceed established performance standards. For instance, in July 2024, Magenta Medical raised USD 105 million to fund U.S. clinical trials of its Elevate heart pump, described as the world’s smallest. The financing, led by Novo Holdings, is expected to support studies in multiple mechanical circulatory support uses and help the company pursue FDA approval for high-risk heart patients.
Similarly, in December 2025, Penn State researchers received a four-year, USD 3.2 million NIH grant to develop a small ventricular assist device for children with heart failure. The project aims to make the pump durable, long-term, and suitable for growing patients, improving the quality of life while they wait for a heart transplant. Such ongoing research and development activities are expected to contribute to market growth.
The rising number of product recalls is a major restraint on the global heart pump devices market. Heart pump devices, including ventricular assist devices (VADs) and total artificial hearts, are highly regulated life-sustaining technologies that require consistent mechanical performance and long-term reliability. Product recalls resulting from manufacturing defects, software malfunctions, component failures, or safety concerns can disrupt product availability and delay clinical adoption. Such recalls are likely to lead to temporary suspension of device implantation, increased regulatory scrutiny, and higher compliance costs for manufacturers. In addition, safety-related incidents can reduce physician confidence and influence hospital purchasing decisions, limiting market growth.
Product recalls also create substantial financial and operational challenges for manufacturers by increasing warranty expenses, product replacement costs, litigation risks, and post-market surveillance requirements. Regulatory authorities often require manufacturers to conduct extensive investigations, implement corrective actions, and strengthen quality management systems before affected products can return to the market.
Company
Product / Component
Product Recall Month/Year
Description
Johnson & Johnson MedTech (Abiomed)
Impella heart pumps (selected CP Sets with SmartAssist)
May-2026
Recall of certain Impella CP Sets with SmartAssist that did not meet design specifications, with FDA communication noting association with at least one patient death.
Johnson & Johnson MedTech (Abiomed)
Impella heart pumps purge cassettes (Gen 1)
Mar-2026
FDA‑confirmed recall of purge cassettes used with multiple Impella heart pumps due to risk of purge cassette leakage, which could impair pump function and patient support.
Johnson & Johnson MedTech (Abiomed)
Automated Impella Controllers
Sep-2025
Recall of specific heart pump controllers after a defect was linked to serious injuries; the company initiated design modifications and device correction campaigns in late 2025.
Abbott
HeartMate 3 and HeartMate II LVAD mobile power units (MPUs)
Aug-2025
Class I recall of power cords/mobile power units after some cords failed to lock into place, creating a risk of sudden loss of power and potentially fatal pump stoppage.
Market Concentration & Characteristics
The heart pump device market is moderately consolidated, with leading players introducing novel products. The market growth stage is high, and the pace of market growth is accelerating. In April 2025, Medtronic received approval from the US FDA for the world's smallest defibrillator lead. This device is designed to stimulate the right ventricle in adult and adolescent pediatric patients aged 12 and older, including those with smaller anatomies, marking a significant advancement in personalized cardiac care.
In July 2024, Magenta Medical Ltd. raised USD 105 million for clinical trials for the Elevate system, the world’s smallest heart pump.
The market is witnessing continuous research and development aimed at advancing cardiac care. In November 2022, LivaNova received 510(k) clearance from the USFDA for the LifeSPARC ECMO machine, allowing it to be used beyond 6 hours for patients with acute cardiopulmonary failure.
In January 2025, the BrioVAD heart pump device, developed by BrioHealth Solutions, Inc., was implanted in patients during a groundbreaking clinical trial. This trial represents a significant opportunity to evaluate cutting-edge technology as we seek to revolutionize treatment options for advanced heart failure.
A moderate level of M&A activities characterizes the heart pump device market. The key reason for the frequent acquisitions in this market is the technological strength of small players with their robust product pipelines. It allows the key players to improve their market share, expand their product portfolio, and provide opportunities to be the first entrant into a niche market segment. For instance, in December 2023, Johnson & Johnson Service Inc. acquired Abiomed, Inc. with the aim of expanding its cardiovascular portfolio. This acquisition is expected to have a positive impact on market growth.
The stringent regulatory framework for the approval and commercialization of heart pump devices impedes market growth. Furthermore, compliance with regulatory standards further results in product recall, which reduces patient and healthcare participant confidence. For instance, In April 2025, the US FDA announced a crucial recall of Abbott’s mobile power units (MPUs) used in HeartMate 3 LVAD and HeartMate II LVAD, prioritizing patient safety and ensuring exceptional performance standards are upheld.
Key companies in the heart pump devices market are also focusing on market expansion. For instance, in October 2023, CorWave SA opened a new production facility to support its commercial and clinical trial phase activities on the banks of the Seine in Clichy, next to Paris. Additionally, in March 2025, Supira Medical successfully raised USD 120 million to advance the clinical development of its innovative temporary heart pump. This groundbreaking device is specifically designed for patients facing high-risk cardiac procedures.
Analyst Perspective
The global heart pump device market is growing steadily due to the rising prevalence of advanced heart failure, cardiogenic shock, and cardiovascular diseases, coupled with the shortage of donor hearts for transplantation. Mechanical circulatory support devices are increasingly used as bridge-to-transplant, bridge-to-recovery, and destination therapy solutions, while advancements in device design and durability continue to support wider clinical adoption. Market competition is driven by innovations in miniaturized implantable devices, magnetically levitated pumps, wireless energy transmission, and AI-enabled monitoring. Manufacturers are focused on reducing complications and improving patient outcomes, while ongoing investments in next-generation artificial hearts and minimally invasive implantation techniques are expected to further drive market growth.
Type Insights
By type, implanted heart pump devices segment held the largest market share of 68.3% in 2025. These devices assume the heart's pumping function by continuously circulating blood from the ventricles throughout the body. The rising prevalence of heart failure and technological advancements in implanted heart pump devices drives market growth. Improved durability, smaller sizes, and enhanced control systems are making these devices more accessible & effective for a wider range of patients. In April 2025, engineers at Northwestern University created the world’s smallest pacemaker, which is small enough to fit inside a syringe's tip and can be injected into the body without surgery. While it is compatible with hearts of all sizes, it is especially designed for the delicate and small hearts of newborns suffering from congenital heart defects.
In addition, this segment is expected to witness the fastest growth with a CAGR over the forecast period. Extracorporeal heart pump products are external devices that temporarily support the heart by pumping blood outside the body and returning it to the circulatory system. They effectively treat acute HF and are used as a bridge to transplantation. The rising prevalence of heart disease and the shortage of donor hearts have driven the demand for extracorporeal products.
Product Insights
By product, the ventricular assist devices (VADs) segment held the largest market share of 69.1% in 2025. VADs are mechanical devices that assist with pumping blood from the heart's ventricles to the rest of the body. They are typically used as a temporary solution while awaiting a heart transplant but are also increasingly being used as a long-term treatment option for HF patients who are not candidates for transplantation.
Market players' introduction of new and advanced VADs is a key factor driving the segment's growth. These products are designed to be more effective, user-friendly, and affordable, which is expected to increase the demand for VADs even further. For instance, in August 2022, Abbott Laboratories disclosed data revealing that patients with advanced heart failure who received its HeartMate 3 LVAD had higher survival rates after five years than those who received the older HeartMate II LVAD. The HeartMate 3 demonstrated a 58% survival rate over the five years, compared to the HeartMate II's 44% survival rate. This is mainly due to decreased deaths related to stroke, clotting, and bleeding associated with the newer device.
In addition, this segment is anticipated to witness the fastest growth with a CAGR over the forecast period. The extracorporeal membrane oxygenation device has been growing due to advancements in technology and its ability to offer a viable solution for patients with end-stage HF awaiting a heart transplant. In September 2024, Medtronic launched the VitalFlow ECMO machine, simplifying therapy and enhancing usability.
End Use Insights
By end use the hospitals segment held the largest market share of 81.5% in 2025. This growth can be attributed to the increasing number of surgical procedures being performed globally due to the rising incidence of cardiovascular diseases and the availability of skilled professionals and novel heart pump products. According to an NIH study in 2023, high-income countries have an average of 123.2 cardiac surgeries per 100,000 population yearly. In December 2024, KMC Hospital, in Mangaluru, partnered with Dr. Madhan's ECMO Health Care Pvt. Ltd. to introduce the ECMO services. This initiative represents a significant advancement, as it is the first of its kind in coastal Karnataka and Northern Kerala.
However, the cardiac centers segment and is expected to witness the fastest growth during the forecast period from 2026 to 2033, owing to the increasing preference of individuals to undergo surgical interventions in cardiac centers. Leading cardiac centers, such as the Cleveland Clinic in the U.S., St. Thomas' Hospital in the UK, and the German Heart Center Munich in Germany, exemplify the demand for heart pump devices. These centers are renowned for their expertise in treating complex cardiac conditions and are often early adopters of cutting-edge technologies, driving the adoption of heart pump devices and shaping the market landscape.
Regional Insights
North America dominated the heart pump devices market with the largest revenue share of 54.6% in 2025. The rising incidence of cardiovascular disease, advanced healthcare infrastructure, and the presence of key players. In addition, the increasing number of patients undergoing surgeries and the rising awareness about minimally invasive surgeries are expected to propel market growth in North America.
U.S. Heart Pump Device Market Trends
The heart pump devices market in the U.S. held the largest share in the North America region in 2025, advanced healthcare infrastructure, the growing patient pool, and the increasing number of new product launches are some of the major factors expected to propel revenue share. In December 2024, BiVacor completed the initial phase of its FDA-approved early feasibility study (EFS) for the Total Artificial Heart (TAH), marking a significant advancement in cardiac innovation.
Europe Heart Pump Device Market Trends
The Heart Pump devices market in Europe held the second-largest revenue market share in 2024. According to the WHO report, in 2024, cardiovascular diseases (CVDs) are the leading cause of disability and premature death in the European Region, accounting for over 42.5% of all deaths annually, which is equal to 10,000 deaths each day. This number is expected to rise in the coming years, indicating a growing need for advanced treatment options such as heart pumps . In May 2024, MOBYBOX, the world’s first integrated portable pneumatic ECMO machine, commercially deployed its first batch in Europe.
The heart pump device market in the UK held the second-largest market share in 2024. The prevalence of cardiovascular diseases, such as coronary artery disease, ischemic heart disease, and other heart-related disorders, is expected to increase the demand for heart pump devices.
France heart pump device market is anticipated to witness significant CAGR during the forecast period. Growth in France is likely driven by rising incidence of cardiovascular diseases, growing number of hospitals & clinics, and lifestyle changes in the population.
Asia Pacific Heart Pump Device Market Trends
Asia Pacific dominated the heart pump device market with a revenue share of 52.59% in 2024.The Asia Pacific heart pump device market is anticipated to grow at a CAGR of 14.1 % during the forecast period. Increasing health awareness, a developing private hospital sector, growing government support and spending, the rising prevalence of cardiovascular diseases, and the growing availability of insurance policies will likely contribute to market growth over the coming decade.
Heart pump device market in China held the largest revenue market share in 2024. The Annual Report on Cardiovascular Health and Diseases in China (2021) estimated that approximately 8.9 million patients in China suffer from heart failure. In addition, in March 2023, Yongrenxin Medical Instrument Co. Ltd. secured nearly USD 100 million in a series A funding to develop a platform for treating heart failures.
Japan heart pump device market held the second largest market share in the Asia Pacific region. Heart disease is the second-leading cause of mortality in Japan, with CHD accounting for about half of heart disease-related deaths. In October 2023, the Icahn School of Medicine at Mount Sinai announced a collaboration with the Chiba Institute of Technology (CIT) to use Artificial Intelligence (AI) for cardiovascular disease research.
Heart pump device market in India is expected to grow at the significant CAGR during the forecast period. Hospital-based studies conducted in Trivandrum and the All-India Institute of Medical Sciences (AIIMS) indicate that rheumatic heart disease (RHD) and coronary artery disease (CAD) are significant contributors to heart failure cases in India. Heart failure stands out as the most common reason for cardiac-related hospitalizations, affecting approximately 1% of the general population annually, which translates to an estimated 8 to 10 million patients.
Central & South America Heart Pump Device Market Trends
The heart pump device market in Latin America is driven by several factors. One key driver is the increasing prevalence of cardiovascular diseases in the region, particularly among the aging population. The rise in lifestyle-related risk factors such as obesity and diabetes also contributes to the growing demand for heart pump devices.
The heart pump device market in Mexico is expected to grow due to various factors, such as the high incidence of chronic heart diseases, a growing population, and the increasing prevalence of cardiovascular diseases. There is a rising demand for advanced cardiac therapies. The market is witnessing a shift toward more innovative and efficient devices, driven by advancements in technology and increasing awareness among healthcare providers and patients.
Middle East & Africa Heart Pump Device Market Trends
MEA heart pump devices market is expected to grow at a lucrative rate. The region faces a significant burden of cardiovascular diseases, including heart failure, which has led to an increased demand for advanced cardiac therapies. With a rising aging population and an increase in lifestyle-related risk factors, such as hypertension & diabetes, the need for innovative solutions in cardiac care is becoming more pronounced.
The heart pump device market in South Africa held the largest revenue market share in 2024. Another trend driving the market is the growing prevalence of cardiovascular diseases in South Africa, particularly among the aging population. This has created a higher demand for advanced cardiac therapies, including heart pump devices and artificial hearts, to improve patient care and outcomes.
Key Heart Pump Device Company Insights
Leading companies in the heart pump devices market are enhancing their offerings and incorporating new technologies to expand their customer reach, secure a greater market share, and diversify their application range.
Key Heart Pump Device Companies:
The following key companies have been profiled for this study on the heart pump device market.
-
Abbott
-
ABIOMED (Johnson & Johnson Services, Inc.)
-
Getinge
-
LivaNova PLC
-
Berlin Heart
-
Picard Medical, Inc. (SynCardia Systems, LLC)
-
Jarvik Heart, Inc.
-
BiVACOR Inc.
-
Leviticus Cardio
-
Teleflex Incorporated.
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Abbott, ABIOMED (Johnson & Johnson Services, Inc.), Getinge, LivaNova PLC, Teleflex Incorporated)
- Expand heart pump device portfolios through continuous product innovation, strategic acquisitions, clinical research, and partnerships with cardiac centers and healthcare institutions. Invest in ventricular assist devices (VADs), extracorporeal life support systems, minimally invasive circulatory support technologies, AI-enabled patient monitoring, and next-generation heart failure management solutions to strengthen market leadership. Focus on enhancing device durability, improving hemodynamic performance, reducing complications, and expanding indications for advanced heart failure and cardiogenic shock management.
- Strong global brand recognition, extensive clinical validation, broad cardiovascular device portfolios, and established relationships with hospitals, cardiac surgeons, and interventional cardiologists. Significant R&D capabilities, regulatory expertise, large-scale manufacturing infrastructure, and global commercial networks enable widespread adoption across advanced heart failure and critical care settings.
- High product development, clinical trial, and regulatory compliance costs can affect profitability and commercialization timelines. Premium-priced heart pump devices, complex implantation procedures, and reimbursement variability may limit adoption in cost-sensitive healthcare systems and emerging markets.
Emerging & Specialized Players (Berlin Heart, SynCardia Systems (Picard Medical, Inc.), Jarvik Heart, Inc., BiVACOR Inc., Leviticus Cardio)
- Focus on specialized mechanical circulatory support technologies including pediatric ventricular assist devices, total artificial hearts, compact implantable heart pumps, magnetically levitated systems, and fully implantable wireless-powered devices. Leverage niche expertise, focused clinical innovation, targeted product development, and collaborations with leading cardiac centers to address unmet needs in advanced heart failure and bridge-to-transplant therapies.
- Greater agility in developing breakthrough technologies for specialized heart failure applications and high-risk patient populations. Ability to rapidly innovate in implant miniaturization, wireless energy transfer, magnetic levitation, and long-term circulatory support, addressing unmet clinical needs beyond conventional ventricular assist devices.
- Limited commercial scale, narrower product portfolios, and lower financial resources compared to multinational cardiovascular device companies. Dependence on clinical trial success, regulatory approvals, and specialized cardiac centers may delay commercialization and restrict broader market penetration.
Recent Developments
-
In March 2025, The ACC (American College of Cardiology) and AHA (American Heart Association) updated their ACS (Acute coronary syndrome) treatment guidelines, upgrading Impella use in STEMI-related cardiogenic shock from Class 2b to 2a, citing improved survival benefits.
-
In December 2024, Daya General Hospital (Kerala, India) inaugurated the ECMO service to improve the outcomes of critically ill patients.
-
In November 2024, Abbott announced the launch of the AVEIR VR single-chamber ventricular leadless pacemaker in India, designed specifically for patients experiencing slow heart rhythms.
-
In November 2023, BiVACOR Inc. received USD 13 million as a grant from the Australian Government's Medical Research Future (MRFF) under the Artificial Heart Frontiers Program (AHFP) to support clinical trials for total artificial heart devices.
-
In April 2023, Abbott obtained two new authorizations from the U.S. FDA for its leading life support system, CentriMag Blood Pump. With this clearance, the CentriMag Blood Pump can be used longer-term in adults during ECMO procedures.
Heart Pump Device Market Report Scope
Report Attribute
Details
Market size in 2025
USD 4.7 billion
Estimated market size in 2026
USD 5.3 billion
Projected market size by 2033
USD 11.0 billion
Growth rate
CAGR of 11.1% from 2026 to 2033
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Type, product, end use, and region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Abbott; ABIOMED (Johnson & Johnson Services, Inc.); Getinge; LivaNova PLC; Berlin Heart; Picard Medical, Inc. (SynCardia Systems, LLC); Jarvik Heart, Inc.; BiVACOR Inc.; Leviticus Cardio; Teleflex Incorporated.
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Heart Pump Device Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global heart pump device market report based on type, product, end use, and region.
-
Type Outlook (Revenue, USD Billion, 2021 - 2033)
-
Implanted Heart Pump Devices
-
Extracorporeal Heart Pump Devices
-
-
Product Outlook (Revenue, USD Billion, 2021 - 2033)
-
Ventricular Assist Devices (VADs)
-
Left Ventricular Assist Devices (LVADs)
-
Right Ventricular Assist Devices (RVADs)
-
BiVAD Ventricular Assist Devices (BiVADs)
-
Percutaneous Ventricular Assist Devices (PVADs)
-
-
Intra-Aortic Balloon Pumps (IABPs)
-
Extracorporeal Membrane Oxygenation (ECMO)
-
-
End Use Outlook (Revenue, USD Billion, 2021 - 2033)
-
Hospitals
-
Cardiac Centers
-
Research Institute
-
-
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa (MEA)
-
Saudi Arabia
-
South Africa
-
UAE
-
Kuwait
-
-
Research Methodology
The heart pump device market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each heart pump device segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Product
Revenue capture definition
Ventricular Assist Devices (VADs)
Mechanical circulatory support devices designed to assist one or both ventricles in pumping blood throughout the body. VADs are used in patients with severe heart failure to improve cardiac output and maintain adequate blood circulation.
Left Ventricular Assist Devices (LVADs)
Implantable mechanical pumps that assist the left ventricle, the heart's primary pumping chamber, in delivering oxygenated blood to the body. LVADs are the most widely used VADs for patients with advanced left-sided heart failure.
Right Ventricular Assist Devices (RVADs)
Mechanical support devices designed to assist the right ventricle in pumping deoxygenated blood to the lungs. RVADs are typically used in patients experiencing right ventricular failure following cardiac surgery, myocardial infarction, or LVAD implantation.
BiVAD Ventricular Assist Devices (BiVADs)
Mechanical circulatory support systems that simultaneously assist both the left and right ventricles. BiVADs are used in patients with severe biventricular heart failure when support of both pumping chambers is required.
Percutaneous Ventricular Assist Devices (PVADs)
Minimally invasive heart pump devices inserted through peripheral blood vessels using catheter-based techniques. PVADs provide temporary circulatory support during high-risk percutaneous coronary interventions (PCI), cardiogenic shock, and other acute cardiac conditions.
Intra-Aortic Balloon Pumps (IABPs)
Mechanical circulatory support devices that use an inflatable balloon positioned within the descending aorta to improve coronary blood flow and reduce cardiac workload through synchronized inflation and deflation with the cardiac cycle. IABPs are primarily used for temporary hemodynamic support in acute cardiac conditions.
Extracorporeal Membrane Oxygenation (ECMO)
Advanced life-support systems that provide temporary cardiac and/or respiratory support by circulating blood through an external membrane oxygenator before returning it to the patient's circulation. ECMO is used in patients with severe cardiac failure, respiratory failure, or combined cardiopulmonary dysfunction.
Segment - Type
Revenue capture definition
Implanted Heart Pump Devices
Mechanically implanted circulatory support devices that are surgically placed inside the patient's body to assist or replace the pumping function of a failing heart. These devices are primarily used for long-term management of advanced heart failure as a bridge to transplant, bridge to recovery, bridge to candidacy, or destination therapy.
Extracorporeal Heart Pump Devices
Mechanical circulatory support systems located outside the patient's body that temporarily assist cardiac function and blood circulation. These devices are commonly used in emergency care, intensive care units, and during cardiac surgery to provide short-term hemodynamic support for patients with acute heart failure or cardiogenic shock.
Segment - End Use
Revenue capture definition
Hospitals
General and specialty hospitals that utilize heart pump devices for the treatment of advanced heart failure, cardiogenic shock, cardiac surgery, and critical care. Hospitals perform device implantation, acute circulatory support, patient monitoring, and long-term management of patients requiring mechanical circulatory support.
Cardiac Centers
Specialized cardiovascular hospitals and heart institutes dedicated to the diagnosis and treatment of complex cardiac disorders. These centers perform advanced procedures such as ventricular assist device implantation, ECMO therapy, high-risk cardiac interventions, and heart transplantation.
Research Institute
Academic institutions, cardiovascular research centers, and clinical research organizations engaged in the development, evaluation, and clinical investigation of heart pump technologies, novel circulatory support devices, biomaterials, and next-generation cardiac assist systems.
Estimation Model
Market Estimation Process:
Market-specific Research Models:
Consensus-Based Estimates & Forecasting
The heart pump devices market presents emerging dominant opportunities, featuring global key players such as Abbott; ABIOMED (Johnson & Johnson Services, Inc.); Getinge; LivaNova PLC; Berlin Heart; Picard Medical, Inc. (SynCardia Systems, LLC); Jarvik Heart, Inc.; BiVACOR Inc.; Leviticus Cardio; Teleflex Incorporated. To ensure a holistic approach, the GVR research team adopted a comprehensive methodology, considering multiple companies worldwide and utilizing various variables for data accuracy.
Our methodology included:
Model 1: Commodity Flow Analysis - For public players, annual reports were referenced. For private players, premium paid data sources such as S&P Global, Crunchbase, ZoomInfo, RocketReach, etc., were used for the latest revenue insights.
Model 2: Parent Market Analysis
Model 3: Country-level Multivariate Analysis Assumptions
Model 4: Segment-level Multivariate Analysis Assumptions
Model 5: Heart Pump Devices Market CAGR Calculations
Model 1: Commodity Flow Analysis
Commodity flow analysis was employed to track the movement of heart pump devices through the value chain, from technology providers to end users. This analysis provided insights into demand generation points, intermediary roles, and ultimate consumption patterns.
Delivered Customizations
This report has been delivered with the following In-depth customizations
CLIENT REQUEST
CUSTOMIZATION DELIVERED
VALUE ADDS
Heart Pump Device Adoption & Advanced Cardiac Support Analysis
Developed a tailored analysis of the global heart pump device market focused on ventricular assist devices (VADs), total artificial heart (TAH), percutaneous heart pumps, extracorporeal mechanical circulatory support systems, and implantable cardiac assist technologies. The study assessed adoption trends across hospitals, cardiac specialty centers, heart failure clinics, and transplant centers while evaluating the growing prevalence of advanced heart failure, increasing cardiovascular disease burden, expanding heart transplantation programs, and demand for long-term mechanical circulatory support influencing market growth.
Enables stakeholders to understand evolving cardiac care trends, identify high-growth heart pump device segments, assess procedure-driven demand opportunities, and evaluate the impact of technological advancements, expanding clinical indications, and healthcare infrastructure development on long-term market expansion.
Mechanical Circulatory Support Technologies, Clinical Outcomes & Cardiac Innovation Assessment
Delivered a customized evaluation of heart pump device utilization across bridge-to-transplant (BTT), destination therapy (DT), bridge-to-recovery (BTR), and bridge-to-decision (BTD) applications. The analysis assessed advancements in continuous-flow ventricular assist devices, magnetically levitated pumps, fully implantable systems, wireless energy transmission technologies, biocompatible materials, and portable circulatory support platforms. Additionally, it evaluated clinical outcomes, patient survival, complication management, quality-of-life improvements, physician adoption patterns, and innovations from leading companies including Abbott, ABIOMED (Johnson & Johnson), Getinge, LivaNova PLC, Berlin Heart, SynCardia Systems, Jarvik Heart, EVAHEART, and Teleflex Incorporated.
Provides actionable insights into commercially attractive device categories, emerging mechanical circulatory support technologies, evolving clinical requirements, and growth opportunities associated with minimally invasive implantation techniques, improved device durability, enhanced patient mobility, optimized heart failure management, and expanded cardiac care therapies.
Cardiovascular Care Infrastructure, Regulatory Environment & Competitive Landscape Assessment
Conducted a focused assessment of the heart pump device ecosystem, including device manufacturing, component supply chains, hospital procurement, reimbursement frameworks, regulatory approval pathways, transplant center adoption, clinical evidence generation, and competitive positioning. The analysis evaluated market access barriers, product innovation strategies, pricing dynamics, physician training requirements, post-market surveillance obligations, technology adoption trends, and competitive differentiation initiatives among leading market participants such as Abbott, ABIOMED (Johnson & Johnson), Getinge, LivaNova PLC, Berlin Heart, SynCardia Systems, Jarvik Heart, BVADCOR, Leviticus Cardio, and ReliantHeart.
Supports strategic planning for product development, clinical commercialization, manufacturing investments, regulatory compliance, healthcare partnerships, geographic expansion, and market entry initiatives by identifying demand drivers, reimbursement trends, operational challenges, revenue opportunities, technology adoption patterns, and competitive advantages across the global heart pump device value chain.
Frequently Asked Questions About This Report
North America dominated with a 54.6% revenue share in 2025.
Asia Pacific is the fastest-growing region over the forecast period.
The Ventricular Assist Devices (VADs) segment accounted for the largest share of 69.1% in 2025, and it is estimated to register growth at the fastest CAGR during the forecast period.
The hospitals segment accounted for the largest share of 81.5% in 2025. However, the cardiac centers segment is estimated to register growth at the fastest CAGR during the forecast period.
The global heart pump device market size was estimated at USD 4.7 billion in 2025 and is expected to reach USD 5.3 billion in 2026.
The global heart pump devices market is expected to grow at a compound annual growth rate of 11.1% from 2026 to 2033 to reach USD 11.0 billion by 2033.
The implanted heart pump devices segment accounted for the largest share of 68.3% in 2025, and it is estimated to register growth at the fastest CAGR during the forecast period.
Some key players operating in the heart pump devices market include Abbott; ABIOMED (Johnson & Johnson Services, Inc.); Getinge; LivaNova PLC; Berlin Heart; Picard Medical, Inc. (SynCardia Systems, LLC); Jarvik Heart, Inc.; BiVACOR Inc.; Leviticus Cardio; Teleflex Incorporated.
Key factors that are driving the market growth include the increasing prevalence of cardiovascular diseases, the growing aging population, and advancements in technology leading to the development of more efficient and effective heart pump devices.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs — add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
